Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

Status:
Recruiting

Trial end date:
2028-06-01

Target enrollment:

Participant gender:

Prospective, non-randomized, single arm phase II trial with 2 cohorts of ALK+ ALCL treated with nivolumab

Phase 2

Gustave Roussy, Cancer Campus, Grand Paris

Antibodies, Monoclonal
Nivolumab